Mural Oncology (NASDAQ:MURA) Now Covered by HC Wainwright

Analysts at HC Wainwright assumed coverage on shares of Mural Oncology (NASDAQ:MURA) in a research note issued to investors on Thursday, MarketBeat.com reports. The brokerage set a “buy” rating and a $18.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 393.15% from the stock’s previous close.

Several other research firms have also recently commented on MURA. Raymond James began coverage on Mural Oncology in a research note on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 target price on the stock. Rodman & Renshaw began coverage on Mural Oncology in a research report on Friday, June 28th. They set a “buy” rating and a $15.00 price target on the stock.

Mural Oncology Stock Performance

NASDAQ MURA opened at $3.65 on Thursday. The stock has a market capitalization of $61.77 million and a price-to-earnings ratio of -0.35. The stock’s 50 day moving average price is $3.28 and its two-hundred day moving average price is $3.46. Mural Oncology has a 52 week low of $2.88 and a 52 week high of $17.00.

Mural Oncology (NASDAQ:MURA) last released its earnings results on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($1.90) by $0.04. On average, equities research analysts forecast that Mural Oncology will post -7.47 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. BBR Partners LLC acquired a new position in shares of Mural Oncology during the 2nd quarter worth approximately $31,000. Rhumbline Advisers acquired a new position in shares of Mural Oncology during the 2nd quarter worth approximately $34,000. Canada Pension Plan Investment Board acquired a new position in shares of Mural Oncology during the 2nd quarter worth approximately $70,000. Dimensional Fund Advisors LP acquired a new position in shares of Mural Oncology during the 2nd quarter worth approximately $71,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Mural Oncology during the 2nd quarter worth approximately $84,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.